NO20006630L - Farmasöytisk sammensetning for behandlingen av diabetes - Google Patents

Farmasöytisk sammensetning for behandlingen av diabetes

Info

Publication number
NO20006630L
NO20006630L NO20006630A NO20006630A NO20006630L NO 20006630 L NO20006630 L NO 20006630L NO 20006630 A NO20006630 A NO 20006630A NO 20006630 A NO20006630 A NO 20006630A NO 20006630 L NO20006630 L NO 20006630L
Authority
NO
Norway
Prior art keywords
diabetes
treatment
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
NO20006630A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006630D0 (no
Inventor
Hiroyuki Odaka
Masahiro Yamane
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20006630D0 publication Critical patent/NO20006630D0/no
Publication of NO20006630L publication Critical patent/NO20006630L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20006630A 1998-06-30 2000-12-22 Farmasöytisk sammensetning for behandlingen av diabetes NO20006630L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18370098 1998-06-30
PCT/JP1999/003496 WO2000000195A1 (fr) 1998-06-30 1999-06-29 Composition pharmaceutique pour le traitement du diabete

Publications (2)

Publication Number Publication Date
NO20006630D0 NO20006630D0 (no) 2000-12-22
NO20006630L true NO20006630L (no) 2001-02-26

Family

ID=16140426

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006630A NO20006630L (no) 1998-06-30 2000-12-22 Farmasöytisk sammensetning for behandlingen av diabetes

Country Status (16)

Country Link
US (2) US6329403B1 (fr)
EP (1) EP1093370B1 (fr)
KR (1) KR20010043455A (fr)
CN (1) CN1305376A (fr)
AR (1) AR019727A1 (fr)
AT (1) ATE318138T1 (fr)
AU (1) AU754740B2 (fr)
BR (1) BR9911656A (fr)
CA (1) CA2329004C (fr)
DE (1) DE69929996T2 (fr)
DK (1) DK1093370T3 (fr)
ES (1) ES2255316T3 (fr)
ID (1) ID27415A (fr)
NO (1) NO20006630L (fr)
WO (1) WO2000000195A1 (fr)
ZA (1) ZA200006262B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
DE60036367T2 (de) 1999-06-21 2008-05-29 Eli Lilly And Co., Indianapolis Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
EP1295609A4 (fr) * 2000-02-24 2004-11-03 Takeda Chemical Industries Ltd Medicaments contenant des ingredients actifs combines
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
JP2004331500A (ja) * 2001-02-16 2004-11-25 Dainippon Pharmaceut Co Ltd 血中濃度制御製剤
EP1385549A2 (fr) * 2001-03-12 2004-02-04 Novartis AG Combinaison de composes organiques
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US20030008838A1 (en) * 2001-04-03 2003-01-09 Havel Peter J. Method of increasing endogenous leptin production
US20070203225A1 (en) * 2001-04-03 2007-08-30 Havel Peter J Method of increasing endogenous adiponectin production and leptin production
JP2002360666A (ja) * 2001-06-11 2002-12-17 Takeda Chem Ind Ltd コバルト合金を用いた打錠用杵臼
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2003063889A1 (fr) * 2002-01-31 2003-08-07 Joslin Diabetes Center, Inc. Procedes de modulation de la fonction des lymphocytes b
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
EP1388352A1 (fr) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Utilisation d'un agoniste de PPAR-alpha pour traiter l'obesité associée au traitement avec un agonist de PPAR-gamma dans des patients
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7160886B2 (en) * 2003-03-03 2007-01-09 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
US20050187266A1 (en) * 2003-04-15 2005-08-25 Pfizer Inc Alpha substituted carboxylic acids
CA2529984C (fr) 2003-06-26 2012-09-25 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
US7008957B2 (en) * 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
DE602004022319D1 (de) * 2003-11-14 2009-09-10 Vertex Pharma Thiazole udn oxazole als modulatoren von atp-bindungs-kassetten-transportern
US20090111742A1 (en) * 2004-01-26 2009-04-30 Alexei Kharitonenkov Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
WO2005092040A2 (fr) * 2004-03-22 2005-10-06 The Regents Of The University Of California Formulation pour ameliorer la production de leptine et d'adiponectine endogene
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
DE112005002969B4 (de) * 2004-12-03 2016-09-22 Vetco Gray Scandinavia As Hybridsteuerungssystem und -verfahren
KR100697982B1 (ko) * 2005-07-08 2007-03-23 대봉엘에스 주식회사 로시글리타존의 제조방법
KR100697983B1 (ko) * 2005-07-08 2007-03-23 대봉엘에스 주식회사 신규 중간체 및 이를 이용한 피오글리타존의 제조방법
US20070129444A1 (en) * 2005-12-06 2007-06-07 Mallinckrodt Inc. Novel weight reduction composition and uses thereof
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN101453993A (zh) 2006-04-03 2009-06-10 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2008091624A2 (fr) * 2007-01-22 2008-07-31 Teva Pharmaceutical Industries Ltd. Formes polymorphes de bromhydrate de rosiglitazone et leurs procédés de préparation
US7960429B2 (en) * 2007-03-30 2011-06-14 Tioga Pharmaceuticals, Inc Kappa-opiate agonists for the treatment of diarrhea-predominant irritable bowel syndrome
US20090318520A1 (en) 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
WO2012059762A1 (fr) * 2010-11-03 2012-05-10 Arecor Limited Nouvelle composition comprenant du glucagon
CN105188720A (zh) 2012-11-06 2015-12-23 西格丽德治疗公司 用作药物或膳食活性成分的多孔硅材料
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (fr) 2017-03-01 2018-09-07 Rgenix, Inc. Sels pharmaceutiquement acceptables d'acide bêta-guanidinopropionique ayant des propriétés améliorées et utilisations de ceux-ci
IL293721A (en) 2019-12-11 2022-08-01 Inspirna Inc Cancer treatment methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030174C (fr) * 1990-01-10 1996-12-24 Anthony H. Cincotta Procede pour la reduction a long terme des reserves lipidiques, de l'insulinoresistance, de l'hyperinsulinemie et de l'hypoglycemie chez les vertebres
GB9111426D0 (en) * 1991-05-28 1991-07-17 Ici Plc Chemical compounds
DE69219136T2 (de) 1991-08-26 1997-08-28 Pharmacia & Upjohn Co., Kalamazoo, Mich. Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JP2000504021A (ja) 1996-02-02 2000-04-04 メルク エンド カンパニー インコーポレーテッド 糖尿病及び関連疾患状態を治療する方法
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
KR20010043455A (ko) 2001-05-25
EP1093370A1 (fr) 2001-04-25
CA2329004A1 (fr) 2000-01-06
US6329403B1 (en) 2001-12-11
NO20006630D0 (no) 2000-12-22
ID27415A (id) 2001-04-05
US20020086885A1 (en) 2002-07-04
ATE318138T1 (de) 2006-03-15
ZA200006262B (en) 2001-11-02
DE69929996T2 (de) 2006-11-16
CA2329004C (fr) 2009-04-14
DK1093370T3 (da) 2006-05-22
DE69929996D1 (de) 2006-04-27
EP1093370B1 (fr) 2006-02-22
CN1305376A (zh) 2001-07-25
WO2000000195A1 (fr) 2000-01-06
ES2255316T3 (es) 2006-06-16
AU754740B2 (en) 2002-11-21
AR019727A1 (es) 2002-03-13
BR9911656A (pt) 2001-03-20
AU4291499A (en) 2000-01-17

Similar Documents

Publication Publication Date Title
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
DK0941103T3 (da) Farmaceutisk præparat til behandling af diabetes
PT1066027E (pt) Composicao farmaceutica de topiramato
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
DK1052974T3 (da) Farmaceutisk sammensætning indeholdende epothilon
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
NO20005913L (no) Legemiddelsammensetning
DK1196163T3 (da) Farmaceutiske sammensætninger til behandling af insulinresistens
NO20015175D0 (no) Farmasöytisk sammensetning
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
NO20063000L (no) Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav.
FI953180A0 (fi) Sokeritaudin komplikaatioiden hoitamiseen tarkoitetut koostumukset
ID29262A (id) Komposisi farmasi
AU2000276362A1 (en) Composition for the treatment of diabetes
NO20005179D0 (no) Medikament behandling
TR199903132A3 (tr) Metalosan bilesiklerinin aktive edici kompozisyonu.
NO20012106D0 (no) Middel for behandling av benpatobolisme
EE04263B1 (et) Farmatseutiline kompositsioon piperidinoalkanoolantihistamiini ja selle derivaatide biosaadavuse suurendamiseks ning allergiliste reaktsioonide raviks patsiendil
DK1150681T3 (da) Anvendelse af en farmaceutisk sammensætning indeholdende desoxypeganin til behandling af nikotinafhængighed
BR9806083A (pt) Composi-Æo farmac-utica para o tratamento da hapattite c
NO20020784L (no) Medikament for behandling av brudd
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
FI4488U1 (fi) Farmaseuttinen koostumus
NO20012541D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application